Edition:
United States

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

4.78USD
13 Dec 2017
Change (% chg)

$0.03 (+0.53%)
Prev Close
$4.75
Open
$4.70
Day's High
$4.80
Day's Low
$4.70
Volume
7,702
Avg. Vol
21,614
52-wk High
$7.20
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics
Monday, 4 Dec 2017 09:58am EST 

Dec 4 (Reuters) - Axsome Therapeutics Inc ::SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING.  Full Article

Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine
Tuesday, 28 Nov 2017 07:00am EST 

Nov 28 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE.AXSOME THERAPEUTICS INC - ‍PHASE 3 TRIAL ANTICIPATED IN 2018​.AXSOME THERAPEUTICS INC - AXS-07 HAS ‍POTENTIAL FOR "SUPERIOR" EFFICACY AS COMPARED TO CURRENT TREATMENTS​.AXSOME THERAPEUTICS INC - ‍U.S. FDA PRE-INVESTIGATIONAL NEW DRUG APPLICATION​ MEETING WRITTEN GUIDANCE RECEIVED.  Full Article

Axsome Therapeutics reports Q3 loss per share $0.27
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.27.Axsome Therapeutics Inc - ‍Believes its cash as of Sept. 30, 2017 will be sufficient to fund anticipated operations into Q1 of 2019​.  Full Article

Axsome Therapeutics says ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome expected year-end 2017​
Thursday, 7 Sep 2017 07:00am EDT 

Sept 7 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics - ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome (CRPS) is expected year-end 2017​.Axsome Therapeutics Inc - ‍interim analysis results for Coast-1 are now also expected late December 2017 to early January 2018​.  Full Article

Axsome Therapeutics reports Q2 loss per share $0.30
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.30.Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Axsome Therapeutics Inc - cash as of June 30, will be sufficient to fund anticipated operations, based on its current operating plans, into Q1 of 2019​.  Full Article

Axsome Therapeutics announces AXS-06 meets primary endpoint in phase 1 clinical trial
Tuesday, 25 Jul 2017 07:00am EDT 

July 25 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics announces AXS-06 (moseic meloxicam and esomeprazole) meets primary endpoint in phase 1 clinical trial.Axsome Therapeutics Inc - ‍primary endpoint met with 9 times faster time to maximum plasma concentration tmax of meloxicam versus mobic​.Says ‍received, from U.S. FDA, pre-ind written guidance on a proposed clinical developmental plan for AXS-06​.Says ‍believes that AXS-06 is phase 3-ready​.Axsome Therapeutics-‍look forward to further development of AXS-06 and to a data readout for AXS-02 in complex regional pain syndrome anticipated in Q4​.Axsome Therapeutics Inc - ‍AXS-06 was well tolerated with reported adverse events being similar across three treatment arms​.Says ‍there were no serious adverse events in study​.  Full Article

Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation
Monday, 17 Jul 2017 07:00am EDT 

July 17 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation.  Full Article

Axsome appoints John Golubieski as CFO
Thursday, 6 Jul 2017 07:00am EDT 

July 6 (Reuters) - Axsome Therapeutics Inc ::Axsome Therapeutics appoints John Golubieski as chief financial officer.Appointment of John Golubieski as chief financial officer, effective August 4, 2017.Axsome Therapeutics Inc - announced appointment of John Golubieski as chief financial officer, effective August 4, 2017.  Full Article

Axsome Therapeutics Q1 loss per share $0.41
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Axsome Therapeutics Inc :Axsome therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.41.Q1 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.Axsome therapeutics - cash as of march 31, 2017 will be sufficient to fund co's anticipated operations, based on current operating plans, into q1 of 2019.  Full Article

Axsome Therapeutics receives FDA fast track designation for axs-05 for alzheimer’s disease agitation
Monday, 8 May 2017 07:00am EDT 

May 8 (Reuters) - Axsome Therapeutics Inc :Axsome therapeutics receives fda fast track designation for axs-05 for alzheimer’s disease agitation.  Full Article

BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics

* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage: